Literature DB >> 15894902

Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.

Maria Karas1, Yves Lacourcière, A-Robert LeBlanc, Réginald Nadeau, Bruno Dubé, Magdalena Florescu, Maxime Lamarre-Cliche, Luc Poirier, Pierre Larochelle, Jacques de Champlain.   

Abstract

OBJECTIVE: To determine the effects of 8 weeks of therapy with amlodipine, ramipril or telmisartan on the autonomic system over 24 h in hypertensives.
METHODS: After a placebo run-in, 57 patients were included in a prospective randomized open-label design protocol for therapy with amlodipine (5 mg for 4 weeks followed by 10 mg for 4 weeks, n = 22), or ramipril (2.5 mg for 1 week, 5.0 mg for 3 weeks and 10 mg for 4 weeks, n = 17) or telmisartan (80 mg for 8 weeks, n = 18). Autonomic functions were assessed by norepinephrine (NE) and epinephrine (E), as well as by the spectral analysis of heart rate variability (HRV).
RESULTS: The 24-h ambulatory blood pressure, plasma NE and HRV demonstrated the characteristic day-night circadian rhythm in hypertensives. Higher values for SBP and DBP and for NE levels, as well as for spectral analysis components - low frequency band (LF) and low frequency/high frequency (LF/HF) ratio - were found during the day, whereas the HF was higher during the night. In patients treated with amlodipine, the HF decreased significantly during the night, while the LF and the LF/HF ratio increased during the day in association with the rise in NE. The therapy with telmisartan did increase the HF during the night and the day, while ramipril did not influence all HRV components during the night but significantly increased the HF, and decreased the LF/HF ratio during the day. No changes were observed in plasma NE with telmisartan or ramipril, but a 50% increase in NE levels throughout the 24-h period was found in amlodipine-treated patients.
CONCLUSION: These data suggest a sympathetic activation during the day and a decrease in parasympathetic activity during the night after therapy with amlodipine, correlated with increases in plasma NE. In contrast, the therapy with telmisartan significantly increased parasympathetic activity without changes in NE during the night and day. The therapy with ramipril increased the parasympathetic activity only during the day.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894902     DOI: 10.1097/01.hjh.0000170389.69202.53

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  10 in total

1.  The Association of Pediatric Obesity With Nocturnal Non-Dipping on 24-Hour Ambulatory Blood Pressure Monitoring.

Authors:  Ian R Macumber; Noel S Weiss; Susan M Halbach; Coral D Hanevold; Joseph T Flynn
Journal:  Am J Hypertens       Date:  2015-08-26       Impact factor: 2.689

Review 2.  Modulation of the QT interval duration in hypertension with antihypertensive treatment.

Authors:  Jan Klimas; Peter Kruzliak; Simon W Rabkin
Journal:  Hypertens Res       Date:  2015-03-19       Impact factor: 3.872

Review 3.  [Analysis of heart rate variability. Mathematical description and practical application].

Authors:  S Sammito; I Böckelmann
Journal:  Herz       Date:  2014-10-10       Impact factor: 1.443

4.  Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.

Authors:  Jean-Marie Krzesinski; Eric P Cohen
Journal:  Core Evid       Date:  2010-06-15

Review 5.  Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS.

Authors:  Corey B Toal; Peter A Meredith; Henry L Elliott
Journal:  Blood Press       Date:  2012-07-05       Impact factor: 2.835

Review 6.  The Role of Angiotensin Receptor Blockers in the Personalized Management of Diabetic Neuropathy.

Authors:  Danai-Thomais Kostourou; Dimitrios Milonas; Georgios Polychronopoulos; Areti Sofogianni; Konstantinos Tziomalos
Journal:  J Pers Med       Date:  2022-07-30

7.  Correlation between Angiotensin Serum Levels and Very-Low-Frequency Spectral Power of Heart Rate Variability during Hemodialysis.

Authors:  Leonardo Del Valle-Mondragón; Brayans Becerra-Luna; Raúl Cartas-Rosado; Oscar Infante; Héctor Pérez-Grovas; Larissa I Lima-Zapata; Claudia Lerma; José Rodríguez-Chagolla; Raúl Martínez-Memije
Journal:  Life (Basel)       Date:  2022-07-09

8.  Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.

Authors:  Waymon Drummond; Mark A Munger; Mohammed Rafique Essop; Mojdeh Maboudian; Mahmudul Khan; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

9.  Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.

Authors:  Yukai Liu; Ken Chen; Xun Kou; Yu Han; Lin Zhou; Chunyu Zeng
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

10.  Autonomic dysfunction in mild cognitive impairment: evidence from power spectral analysis of heart rate variability in a cross-sectional case-control study.

Authors:  Paola Nicolini; Michele M Ciulla; Gabriella Malfatto; Carlo Abbate; Daniela Mari; Paolo D Rossi; Emanuela Pettenuzzo; Fabio Magrini; Dario Consonni; Federico Lombardi
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.